GammaCan to Present its Anti-Melanoma Technology at the 2007 ILSI BioMed Conference
June 06 2007 - 3:02AM
Business Wire
GammaCan International, Inc. ("GammaCan" or "the Company")
(OTCBB:GCAN), a developer of immunotherapies for the treatment of
cancer, today announced that Patrick Schnegelsberg, Chief Executive
Officer, is scheduled to present VitiGam�, GammaCan's lead product
under development for the treatment of Stage III and Stage IV
melanoma, at the 2007 ILSI BioMed 2007 Conference. The Conference
will be held from June 5th through June 7th at the David
Intercontinental Hotel, in Tel Aviv, Israel. GammaCan�s
presentation is scheduled during the Cancer Session, which will
take place on Wednesday, June 6th, 2007. About GammaCan GammaCan
develops innovative immunotherapy and related approaches to treat
cancer. GammaCan's platform technology is based on the use of IgGs,
a safe, relatively non-toxic human plasma-derived product used to
treat a variety of immune deficiencies and autoimmune diseases. In
cancer, IgG-based therapies work by strengthening the patient's
immune system. Many experts currently view immunotherapy as a
future alternative to chemotherapy. For more information about
GammaCan, visit www.GammaCan.com. About VitiGam� VitiGam� is a
first-in-class IgG-based anti-cancer immunotherapy being developed
for the treatment of Stage III and Stage IV melanoma. GammaCan is
planning to submit its Investigational New Drug Application (IND)
for VitiGam� to the FDA in the near future. The Company expects to
commence human clinical trials shortly thereafter. VitiGam� is an
IgG-based product manufactured from the plasma of donors with
Vitiligo, a benign skin condition affecting up to 2% of the general
population. Studies have shown that this "enriched" IgG formulation
contains potent anti-melanoma activity. Based on these studies,
GammaCan expects VitiGam� to provide both, specific anti-melanoma
activity (directed against melanoma cells), and non-specific
anti-cancer activity. About Melanoma Melanoma is a deadly form of
skin cancer. According to the American Cancer Society, melanoma
accounts for approximately 4% of all skin cancers but causes about
75% of all skin cancer-related deaths. An estimated 62,000 people
will be diagnosed with and nearly 8,000 people will die from
melanoma in the U.S. alone in 2007. If rapidly diagnosed and
surgically removed, early-stage melanoma is usually curable.
However, for patients with metastatic melanoma (including Stage II
and Stage IV), the prognosis is poor resulting from limited
treatment alternatives, a median survival time of 8.5 months, and a
5-year survival rate of 3%. There has been little change in these
results for in excess of 25 years. The incidence of melanoma has
increased more rapidly than any other cancer during the past 10
years. The last drug to treat patients with metastatic melanoma was
approved by the FDA over 30 years ago. Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this
release include statements regarding: the commercialization of
anti-cancer immunotherapies and the Company's efforts to develop
therapies to boost the immune systems of cancer patients by the use
of IgG-based therapy. Actual outcomes and the Company's actual
results could differ materially from those in such forward-looking
statements. Factors that could cause actual results to differ
materially include risks and uncertainties such as the inability to
finance the planned development of the technology, the inability to
hire appropriate staff to develop the technology, unforeseen
technical difficulties in developing the technology, the inability
to obtain regulatory approval for human use, competitors' therapies
proving to be more effective, cheaper or otherwise preferable for
consumers, the inability to market a product, all of which could,
among other things, delay or prevent product release, as well as
other factors expressed from time to time in GammaCan's periodic
filings with the Securities and Exchange Commission (the "SEC"). As
a result, this press release should be read in conjunction with
GammaCan's periodic filings with the SEC, which are incorporated
herein by reference. The forward-looking statements contained
herein are made only as of the date of this press release, and
GammaCan undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or
circumstances.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024